For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.
Vanessa Caceres is a freelance medical writer and editor based in Florida. She has a BA in journalism and psychology and a Master's degree in teaching English as a second language/bilingual education. She writes regularly for ophthalmology and rheumatology physician publications, as well as other specialties.
Articles by Vanessa Caceres
Researchers Should Use ACR/EULAR Definition of RA Remission in Clinical Studies
Clinical trials in rheumatoid arthritis (RA) should use the new ACR/EULAR remission definition rather than the Disease Activity Score-28-CRP, which does not sufficiently reflect patient outcomes, according to an ACR/EULAR committee.
Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout
A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…
Updates in Osteoarthritis: Research Provides Insights into Molecular Pathogenesis of OA
In the ACR Convergence 2021 session on Updates in OA, presenters discuss the debate over OA phenotypes vs. endotypes, as well as note that research conducted over the past 20 years yields a better understanding of the pathogenesis of OA.
Advances in Rheumatology & Challenges that Remain Spotlighted in ACR Convergence 2021 Closing Session
The diverse topics, research & perspectives from this year’s ACR Convergence bring new insights for rheumatologists & all who care for their patients, according to speakers at the meeting’s Closing Session.
Precision Medicine in Lupus
Targeted treatments for lupus still have a long way to go, but some studies are starting to pinpoint potential treatment pathways.
Business Rheum: What to Expect from New MVP Measures
The new rheumatology-specific Merit-Based Incentive Payment System Value Pathway will focus on measures that most rheumatologists already track. The model should streamline reporting and better target quality improvements.
Opening Session of ACR Convergence 2021 Takes on Burnout, Pandemic Challenges & Moving Toward a New Normal
Keynote speaker Seema Yasmin, MD, brought her unique perspective to moving past the pandemic to improve provider mental health, address vaccine hesitancy and prepare for future health crises.
Business of Rheum Session to Outline What to Expect with MIPS Value Pathways
The MIPS Value Pathways will streamline federal reporting to better incentivize quality improvement. Start preparing for MVP with this session at ACR Convergence 2021.
Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 15
- Next Page »